Neurologists React to CMS’ Finalized NCD Decision on Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease

Spherix captures potential impact on Eisai/Biogen's lecanemab, Eli Lilly's donanemab, and Roche/Genentech's gantenerumab EXTON, Pa., May 16, 2022 /PRNewswire/ -- On April 7, 2022, CMS finalized its NCD for anti-amyloid monoclonal antibodies (mAbs) for the treatment of Alzheimer's disease....

Click to view original post